CTAD26: Advancing Alzheimer’s Disease Clinical Research Together
The 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference will take place in Boston, USA, on November 16–19, 2026.
Since 2008, CTAD has served as a global forum dedicated exclusively to Alzheimer’s disease clinical research, bringing together investigators, clinicians, industry scientists, and regulatory experts committed to advancing the field.
CTAD is designed as a focused scientific meeting. All sessions are held in a single main ballroom, ensuring that the entire community shares the same presentations and discussions. This unified format fosters a collective scientific experience, encourages in-depth dialogue, and creates meaningful interactions across disciplines.
The conference offers an opportunity to engage with key opinion leaders, clinical trialists, regulatory representatives, and multidisciplinary research teams, while gaining insight into the latest advances shaping prevention and treatment strategies.
You are warmly invited to Boston for CTAD26. Together, through open dialogue and shared scientific commitment, we can continue to advance Alzheimer’s disease research and improve outcomes for patients worldwide.